Comparison of POSEIDON Pivotal Cohort vs. NACSELD-III Supports Strong Commercial Messaging for alfapump Poster presentation by Dr. Jasmohan S. Bajaj on 7 June 2024 Ghent, Belgium – 10 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure...Read More